Get the Stockscreener App
44.84
1.47%
0.59
Royalty Pharma Plc stock is traded at $44.84, with a volume of 3.26M.
It is up +1.47% in the last 24 hours and up +11.52% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$44.25
Open:
$44.24
24h Volume:
3.26M
Relative Volume:
0.83
Market Cap:
$19.16B
Revenue:
$2.35B
Net Income/Loss:
$1.30B
P/E Ratio:
25.64
EPS:
1.7487
Net Cash Flow:
$1.05B
1W Performance:
+1.81%
1M Performance:
+11.52%
6M Performance:
+25.21%
1Y Performance:
+38.83%
1-Day Range:
$44.05
$45.27
1-Week Range:
$42.50
$45.27
52-Week Range:
$29.66
$45.27
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
44.84 | 18.91B | 2.35B | 1.30B | 1.05B | 1.7487 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.10 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.70 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
839.57 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.25 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.45 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View (NASDAQ:RPRX) - Seeking Alpha
Royalty Pharma price target raised to $51 from $45 at Goldman Sachs - TipRanks
Royalty Pharma plc (NASDAQ:RPRX) Q4 2025 Earnings Call Transcript - Insider Monkey
BofA Securities reiterates Buy rating on Royalty Pharma stock with $54 target - Investing.com Nigeria
BofA Securities Reiterates Buy Rating on Royalty Pharma (RPRX) - StreetInsider
Royalty Pharma's Disciplined Capital Allocation Approach and Appealing Market Growth Bolster Outlook - Morningstar
Royalty Pharma Q4 2025 slides: double-digit growth amid synthetic royalty expansion - Investing.com Nigeria
Royalty Pharma stock hits 52-week high at 44.94 USD By Investing.com - Investing.com Nigeria
Royalty Pharma targets 3%–8% royalty receipts growth in 2026 while advancing $4.7B in transactions - MSN
Royalty Pharma earnings beat by $0.22, revenue fell short of estimates - Investing.com UK
Royalty Pharma plc (RPRX) Reports Q4 results - StreetInsider
Royalty Pharma earnings beat by $0.22, revenue topped estimates - Investing.com Nigeria
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.235 - simplywall.st
Royalty Pharma (NASDAQ:RPRX) Releases Earnings Results, Misses Expectations By $0.90 EPS - MarketBeat
RPRX: Double-digit growth, early capital deployment, and rising synthetic royalties drive strong outlook - TradingView
Earnings call transcript: Royalty Pharma beats Q4 2025 forecasts with strong EPS - Investing.com India
RPRX: Double-digit growth, early capital deployment, and strong 2026 outlook with cost savings - TradingView
Royalty Pharma Q4 Earnings Call Highlights - Yahoo Finance
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings - Yahoo Finance
Royalty Pharma plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Royalty Pharma plc Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Royalty Pharma plc SEC 10-K Report - TradingView
Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings - Finviz
Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shares Dip Despite Strong Portfolio Growth and 2026 Guidance Beat - ChartMill
Royalty Pharma Reports Q4 and Full Year 2025 Results - TradingView
Royalty Pharma's Q4 Net Income, Revenue Rise - marketscreener.com
Royalty Pharma reports Q4 portfolio receipts of $874M - TipRanks
Royalty Pharma Plc Bottom Line Advances In Q4 - Nasdaq
Royalty Pharma Q4 Earnings Report: What Investors Need to Know - Benzinga
Royalty Pharma earnings in focus after $4.7B deal spree By Investing.com - Investing.com South Africa
Royalty Pharma earnings in focus after $4.7B deal spree - Investing.com
Royalty Pharma's Earnings: A Preview - Benzinga
Exploring Analyst Estimates for Royalty Pharma (RPRX) Q4 Earnings, Beyond Revenue and EPS - Yahoo Finance Australia
UBS and Citi are bullish on Royalty Pharma plc (RPRX) – here’s why - MSN
UBS and Citi Are Bullish on Royalty Pharma Plc (RPRX) – Here’s Why - Insider Monkey
Allianz Asset Management GmbH Sells 127,319 Shares of Royalty Pharma PLC $RPRX - MarketBeat
What To Expect From Royalty Pharma's (RPRX) Q4 Earnings - Finviz
What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings - Yahoo Finance UK
Alps Advisors Inc. Acquires New Shares in Royalty Pharma PLC $RPRX - MarketBeat
Shorts Report: Will Royalty Pharma plc benefit from rate cutsJuly 2025 Outlook & Stock Timing and Entry Methods - baoquankhu1.vn
Rally Mode: Should I add Phoenix Laser Systems Inc Preferred Security stock to my portfolio2025 Market Sentiment & Weekly High Momentum Picks - baoquankhu1.vn
Thrivent Financial for Lutherans Trims Stake in Royalty Pharma PLC $RPRX - MarketBeat
The Best Biotech Stocks to Buy - Morningstar
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Finviz
Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma EVP Coyne sells $10.3 million in shares By Investing.com - Investing.com UK
C WorldWide Group Holding A S Raises Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Homestead Advisers Corp Sells 37,000 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma EVP Coyne sells $10.3 million in shares - Investing.com
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Royalty Pharma Plc Stock (RPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Coyne Terrance P. | EVP & CFO |
Feb 02 '26 |
Sale |
42.08 |
108,424 |
4,562,905 |
30,167 |
| Coyne Terrance P. | EVP & CFO |
Feb 04 '26 |
Sale |
43.29 |
20,163 |
872,913 |
22,885 |
0.17%
3.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):